Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection

Table 1 Demographics of patients and characteristics of bloodstream infection

Characteristic
Male	52 (48%)
Median age, years	71 (IQR 57, 83)
Median days in hospital before bloodstream infection	0 (IQR 0, 1)
Median inpatient days after bloodstream infection	8 (IQR 5, 12)
Number admitted to OPAT	38 (35%)
Polymicrobial bloodstream infection^a	6 (6%)
Source of infection
Complicated UTI	46 (43%)
Uncomplicated UTI	35 (32%)
Intra-abdominal other than biliary tract	11 (10%)
Biliary tract	7 (6%)
Febrile neutropenia	4 (4%)
No focus	4 (4%)
Native osteomyelitis	1 (1%)
Total duration of antimicrobial therapy, median, days	15 (IQR 12, 17)
Number treated with carbapenem	102 (94%)
Number de-escalated to oral therapy^b	45 (42%)
Median duration oral therapy, days	12 (IQR 6, 15)
30-day mortality^c	11/99 (11%)

OPAT outpatient antimicrobial therapy, UTI urinary tract infection
^a 1 patient was bacteremic with both S. agalactiae and P. mirabilis, 2 patients had Staphylococcus aureus, 1 patient had Streptococcus anginosus group, 1 patient had Pseudomonas aeruginosa, 1 patient had Enterococcus raffinosus
^b 29 patients given ciprofloxacin, 10 trimethoprim-sulfamethoxazole, 3 trimethoprim, 2 oral fosfomycin, 1 nitrofurantoin,
^c 30-day follow-up not available for 9 patients

ISSN: 1476-0711